Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Leukemia

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 27 articles: HTML format

Single Articles

May 2025
1. BAYET M, Fregona V, Bouttier M, Rouzier C, et al
   Modeling the PAX5P80R Mutation Reveals HIF2alpha Activation as a Common Feature and Therapeutic Target in B-Cell Acute Lymphoblastic Leukemia.
   Cancer Res. 2025 May 12. doi: 10.1158/0008-5472.CAN-24-1698.
   PubMed     Abstract available
   
   
   
2. CHEN Y, He L, Ianevski A, Nader K, et al
   A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia.
   Cancer Res. 2025 May 12. doi: 10.1158/0008-5472.CAN-24-3840.
   PubMed     Abstract available
   
   
   April 2025
3. HUBBARD AK, Brown DW, Liu J, Chan IC, et al
   Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification.
   Cancer Res. 2025 Apr 30. doi: 10.1158/0008-5472.CAN-24-4251.
   PubMed     Abstract available
   
   
   March 2025
4. ZHOU M, Wu Z, Wei F, Duan C, et al
   SMYD3 Activates Fatty Acid beta-oxidation to Promote Self-Renewal of Leukemia Stem Cells.
   Cancer Res. 2025 Mar 13. doi: 10.1158/0008-5472.CAN-24-2117.
   PubMed     Abstract available
   
   
   
5. OROFINO G, Toffalori C, Vago L
   In the Right Place and the Right State: Spatial Crosstalk and Immune State Dictate Leukemia Response to Immunotherapy.
   Cancer Res. 2025 Mar 11. doi: 10.1158/0008-5472.CAN-25-1018.
   PubMed     Abstract available
   
   
   December 2024
6. CERMAKOVA K, Hodges HC
   Pharmacologic Blockade of a Pioneer Transcription Factor.
   Cancer Res. 2024;84:4124-4125.
   PubMed     Abstract available
   
   
   
7. LIU X, Liu Y, Rao Q, Mei Y, et al
   Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells.
   Cancer Res. 2024;84:4233-4245.
   PubMed     Abstract available
   
   
   November 2024
8. ZHAI F, Pan G, Xue L, Cheng C, et al
   PRDM16 Induces Methylation of FLT3 to Promote FLT3-ITD Signaling and Leukemia Progression.
   Cancer Res. 2024 Nov 4. doi: 10.1158/0008-5472.CAN-24-0577.
   PubMed     Abstract available
   
   
   October 2024
9. LUO Z, Lin C, Yu C, Yuan C, et al
   Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia.
   Cancer Res. 2024 Oct 22. doi: 10.1158/0008-5472.CAN-24-1093.
   PubMed     Abstract available
   
   
   September 2024
10. LUO H, Kharas MG
    Dotting Out AML by Targeting Fibrillarin.
    Cancer Res. 2024;84:2759-2760.
    PubMed     Abstract available
    
    
    August 2024
11. TORRES-DIZ M, Reglero C, Falkenstein CD, Castro A, et al
    An Alternatively Spliced Gain-of-Function NT5C2 Isoform Contributes to Chemoresistance in Acute Lymphoblastic Leukemia.
    Cancer Res. 2024 Aug 2. doi: 10.1158/0008-5472.CAN-23-3804.
    PubMed     Abstract available
    
    
    July 2024
12. SCHNEIDER C, Spaink H, Alexe G, Dharia NV, et al
    Targeting the Sodium-Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia.
    Cancer Res. 2024 Jul 18. doi: 10.1158/0008-5472.CAN-23-3560.
    PubMed     Abstract available
    
    
    
13. HUANG D, Yu Z, Lu H, Jiang P, et al
    Adhesion GPCR ADGRE2 Maintains Proteostasis to Promote Progression in Acute Myeloid Leukemia.
    Cancer Res. 2024;84:2090-2108.
    PubMed     Abstract available
    
    
    June 2024
14. POORT VM, Hagelaar R, van Roosmalen MJ, Trabut L, et al
    Transient Differentiation-State Plasticity Occurs During Acute Lymphoblastic Leukemia Initiation.
    Cancer Res. 2024 Jun 17. doi: 10.1158/0008-5472.CAN-24-1090.
    PubMed     Abstract available
    
    
    
15. BERTOLI RM, Chung YJ, Difilippantonio MJ, Wokasch A, et al
    The DNA methyltransferase inhibitor 5-aza-4'-thio-2'-deoxycytidine induces C>G transversions and acute lymphoid leukemia development.
    Cancer Res. 2024 Jun 4. doi: 10.1158/0008-5472.CAN-23-2785.
    PubMed     Abstract available
    
    
    April 2024
16. BOET E, Sarry JE
    Targeting Metabolic Dependencies Fueling the TCA Cycle to Circumvent Therapy Resistance in Acute Myeloid Leukemia.
    Cancer Res. 2024;84:950-952.
    PubMed     Abstract available
    
    
    February 2024
17. JIN P, Wang X, Jin Q, Zhang Y, et al
    Mutant U2AF1-induced mis-splicing of mRNA translation genes confers resistance to chemotherapy in acute myeloid leukemia.
    Cancer Res. 2024 Feb 28. doi: 10.1158/0008-5472.CAN-23-2543.
    PubMed     Abstract available
    
    
    
18. LIU ZS, Sinha S, Bannister M, Song A, et al
    R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription-Replication Conflicts.
    Cancer Res. 2024;84:577-597.
    PubMed     Abstract available
    
    
    January 2024
19. MONTEITH AJ, Ramsey HE, Silver AJ, Brown D, et al
    Lactate utilization enables metabolic escape to confer resistance to BET inhibition in acute myeloid leukemia.
    Cancer Res. 2024 Jan 29. doi: 10.1158/0008-5472.CAN-23-0291.
    PubMed     Abstract available
    
    
    
20. SU Y, Carter JL, Li X, Fukuda Y, et al
    The imipridone ONC213 targets alpha-ketoglutarate dehydrogenase to induce mitochondrial stress and suppress oxidative phosphorylation in acute myeloid leukemia.
    Cancer Res. 2024 Jan 24. doi: 10.1158/0008-5472.CAN-23-2659.
    PubMed     Abstract available
    
    
    
21. RAUCCI F, Vernieri C, Di Tano M, Ligorio F, et al
    Cyclic fasting-mimicking diet plus bortezomib and rituximab is an effective treatment for chronic lymphocytic leukemia.
    Cancer Res. 2024 Jan 19. doi: 10.1158/0008-5472.CAN-23-0295.
    PubMed     Abstract available
    
    
    
22. WANG P, Zhang Y, Xiang R, Yang J, et al
    Foretinib is effective in acute myeloid leukemia by inhibiting FLT3 and overcoming secondary mutations that drive resistance to quizartinib and gilteritinib.
    Cancer Res. 2024 Jan 17. doi: 10.1158/0008-5472.CAN-23-1534.
    PubMed     Abstract available
    
    
    December 2023
23. MAI S, Hodges A, Chen HM, Zhang J, et al
    LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy.
    Cancer Res. 2023;83:4047-4062.
    PubMed     Abstract available
    
    
    
24. XIA L, Liu JY, Yang MY, Zhang XH, et al
    Osimertinib covalently binds to CD34 and eliminates myeloid leukemia stem/progenitor cells.
    Cancer Res. 2023 Dec 14. doi: 10.1158/0008-5472.CAN-23-1632.
    PubMed     Abstract available
    
    
    October 2023
25. MODI A, Lopez G, Conkrite KL, Su C, et al
    Integrative Genomic Analyses Identify LncRNA Regulatory Networks across Pediatric Leukemias and Solid Tumors.
    Cancer Res. 2023;83:3462-3477.
    PubMed     Abstract available
    
    
    September 2023
26. ZIERHUT C
    p53 and Innate Immune Signaling in Development and Cancer: Insights from a Hematologic Model of Genome Instability.
    Cancer Res. 2023;83:2807-2808.
    PubMed     Abstract available
    
    
    
27. DRESSEL N, Natusch L, Munz CM, Costas Ramon S, et al
    Activation of the cGAS/STING Axis in Genome-Damaged Hematopoietic Cells Does Not Impact Blood Cell Formation or Leukemogenesis.
    Cancer Res. 2023;83:2858-2872.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.